Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Earnings per Common Share - Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Effect of dilutive securities:
Total potentially dilutive securities (in shares)	15,884,328	28,494,561	15,884,328	28,494,561
Warrants to purchase shares of common stock
Effect of dilutive securities:
Total potentially dilutive securities (in shares)	0	14,166,644	0	14,166,644
Options to purchase shares of common stock
Effect of dilutive securities:
Total potentially dilutive securities (in shares)	2,584,248	3,509,029	2,584,248	3,509,029
Outstanding shares in escrow
Effect of dilutive securities:
Total potentially dilutive securities (in shares)	1,041,969	0	1,041,969	0
Outstanding shares in escrow \| Keystone
Effect of dilutive securities:
Total potentially dilutive securities (in shares)			1,041,969
Restricted shares of common stock
Effect of dilutive securities:
Total potentially dilutive securities (in shares)	12,258,111	10,818,888	12,258,111	10,818,888